Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

JAMA Study Demonstrates Efficacy of Life Technologies' Lung Cancer Test

Published: Thursday, November 08, 2012
Last Updated: Thursday, November 08, 2012
Bookmark and Share
Genetic test identifies patients at high risk for mortality in the earliest stage of lung cancer. Study suggests test could maximize the benefits of early screening if used in combination with computed tomography.

Life Technologies Corporation announced publication in the Journal of the American Medical Association1 (JAMA) of a study that underscores the clinical utility of the company's early stage lung cancer test, Pervenio™ Lung RS. Launched in September 2012, the genetic test has now been demonstrated to reliably identify patients who are at high risk for mortality following surgery even for the earliest stage of lung cancer.

The test was initially validated through two independent, blinded retrospective studies involving approximately 1,500 patients, which were published in the March 2012 issue of The Lancet.2 The new study reports data from a subset of patients included in the larger validation studies. Specifically, it looks at those patients with "T1a, node-negative" tumors, cancers that are smaller than two centimeters in diameter and that have no detectable spread of the disease.

"We know that roughly a quarter of patients with T1a, node negative tumors will die within five years, most often with recurrent lung cancer," said Michael Mann, M.D., senior author of the study. "And yet these patients do not receive any chemotherapy following surgery because there are no guidelines for identifying which T1a patients are at high risk for mortality."

Dr. Mann is associate professor of cardiothoracic surgery at the University of California, San Francisco and was involved in the development of the PervenioTM Lung RS test along with co-author David Jablons, M.D., chief of general thoracic surgery at the University of California, San Francisco.

"By the time the disease recurrence can be detected, it is too late for therapies to be curative," said Dr. Jablons. "We know from previous clinical trials that chemotherapy can cure metastatic lung cancer when it is treated even before it can be detected. Therefore, we need to identify the high-risk patients earlier, immediately after surgery if possible. Current published guidelines already recommend consideration of chemotherapy at that time even for stage I patients who are believed to be at the highest risk."

Pervenio™ Lung RS is a genetic test that examines activity of 14 genes in tumor tissue. The current JAMA study demonstrates that the test accurately predicted mortality risk among 269 T1a, node-negative patients. The test categorized 92 patients as high risk; survival among these patients was just over 50 percent. In contrast, survival among patients classified by the test as low risk was nearly 85 percent.  Further, when patients with tumors smaller than one centimeter were examined, 100 percent of the low-risk patients survived, as compared to just over 30 percent of the patients determined to be at high risk by the test.

"Physicians don't need to send these early stage patients home for 'watchful waiting' anymore, knowing that a good percentage of them will see their cancer recur and many of those will die," said Ronnie Andrews, president of Medical Sciences at Life Technologies. "We haven't seen survival rates for early stage lung cancer improve significantly during the past 30 years, but now we have a tool that can help enable more patients to receive a treatment that may increase their survival closer to what we see in diseases in which we have made progress, such as breast and colon cancer."

Five-year survival rates for stage I lung cancer are approximately 60 percent. By comparison, patients with stage I colon or breast cancer can expect surgical cure rates of greater than 90 percent. In addition, genetic testing of tumors may play a role in extending early screening efforts.

"Currently, the issue of screening for lung cancer is somewhat controversial," said Dr. Mann. "One challenge of screening is how to maximize the chances of survival for a dramatically increased number of patients who would be diagnosed at the very earliest stages. Right now, a quarter or more of those patients would still die, despite early detection. The Pervenio™ test could add a layer of sophistication and personalization to the care of that growing population that could improve survival rates even further."

"There is also a movement toward limiting the loss of healthy lung tissue to lung cancer operations," Dr. Jablons added, "but there is concern that important prognostic information currently used in conventional staging might be lost with less radical surgery. Pervenio™ has been shown to provide even more accurate information about prognosis and would therefore enable equal or even better clinical management decisions with lung-sparing operations."

Pervenio™ Lung RS is available through the Life Technologies' Clinical Services Lab, which is licensed in all 50 U.S. states. Life Technologies also plans to make Pervenio™ Lung RS available outside of the United States, so the test can be broadly deployed on Life Technologies' regulated platforms, including the 7500 Fast Dx for qPCR.

The study, titled "Ability of a Prognostic Assay to Identify Patients at High Risk of Mortality Despite Small, Node-Negative Lung Tumors," was supported by private endowments to the UCSF Thoracic Oncology Laboratory and by Pinpoint Genomics, which Life Technologies acquired in July 2012.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Life Technologies to Collaborate with Merck Serono
Long-term collaboration is aimed at developing, obtaining regulatory approval and commercializing companion diagnostics for selected Merck Serono drug development programs.
Wednesday, July 17, 2013
Life Technologies Screening Technology Receives Emergency Use Authorization
Life Technologies supports global effort to help accelerate emergency screening of Novel Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Wednesday, June 26, 2013
Life Technologies Supports Emergency Screening of Avian Influenza (H7N9) Virus
Company's instruments FDA-cleared under Emergency Use Authorization declaration.
Monday, April 29, 2013
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Crystal Clear Images Uncover Secrets of Hormone Receptors
NIH researchers gain better understanding of how neuropeptide hormones trigger chemical reactions in cells.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!